OncoMatch/Clinical Trials/NCT05975749
Adjuvant Serplulimab and Trastuzuma and Chemotherapy in Her-2+ Gastric Cancer
Is NCT05975749 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Serplulimab and Trastuzuma for gastric cancer.
Treatment: Serplulimab · Trastuzuma · Chemotherapy — The purpose of this study is to find out whether treatment with Serplulimab combined with Trastuzumab and Chemotherapy will improve the survival of gastric cancer patients with stage II-III after surgery.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Gastric Cancer
Biomarker criteria
Required: HER2 (ERBB2) overexpression
Her2+ diagnosed by Immunohistochemistry
Required: HER2 (ERBB2) amplification
Her2+ diagnosed by FISH
Disease stage
Required: Stage II, III
Excluded: Stage I, IV
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: chemotherapy
Cannot have received: radiation therapy
Cannot have received: immunotherapy
Cannot have received: targeted therapy
Lab requirements
Blood counts
WBC≥3.5 x 10^9 /L, NEU≥1.2 x 10^9 /L, PLT≥90 x 10^9 /L and HGB≥80g/L
Kidney function
normal kidney function
Liver function
normal liver function
Cardiac function
normal electrocardiogram
normal peripheral blood routine, liver and kidney function and electrocardiogram （WBC≥3.5 x 10^9 /L, NEU≥1.2 x 10^9 /L,PLT≥90 x 10^9 /L and HGB≥80g/L)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05975749 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require ERBB2?
Yes, ERBB2 overexpression is a required biomarker for enrollment.
Does this trial require ERBB2?
Yes, ERBB2 amplification is a required biomarker for enrollment.
What disease stage is eligible?
Stage II or III is required.
Is there an age limit?
Yes. Patients must be 80 years or younger and at least 20 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages